- Home
- XP vs NUVL Comparison
XP vs NUVL Comparison
Compare XP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | NUVL |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.1B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XP | NUVL |
|---|---|---|
| Price | $19.33 | $101.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $22.67 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 6.5M | 435.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $13.67 | $1,064.25 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.20 | $55.54 |
| 52 Week High | $23.13 | $113.02 |
Technical Indicators
Market Signals| Indicator | XP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 49.88 |
| Support Level | $18.05 | $98.65 |
| Resistance Level | $20.37 | $107.13 |
| Average True Range (ATR) | 1.07 | 3.97 |
| MACD | -0.37 | -0.15 |
| Stochastic Oscillator | 23.44 | 50.05 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.